Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model

Haemophilia A patients require perioperative clotting factor replacement to limit excessive bleeding. Weight‐based dosing of Factor VIII (FVIII) does not account for inter‐individual pharmacokinetic (PK) variability, and may lead to suboptimal FVIII exposure.

[1]  F. Leebeek,et al.  Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients , 2021, British journal of clinical pharmacology.

[2]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  H. Zanthoff.  lattice , 2020, Catalysis from A to Z.

[4]  V. Blanchette,et al.  Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. , 2019, Blood.

[5]  A. Iorio,et al.  Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization , 2019, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Xiaoxi Liu,et al.  Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method , 2019, CPT: pharmacometrics & systems pharmacology.

[7]  E. Neufeld,et al.  Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations , 2018, Research and practice in thrombosis and haemostasis.

[8]  M. Tortorici,et al.  Population pharmacokinetics of recombinant coagulation factor VIII‐SingleChain in patients with severe hemophilia A , 2017, Journal of thrombosis and haemostasis : JTH.

[9]  N. Holford,et al.  Allometric size: The scientific theory and extension to normal fat mass , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  E. Duncan,et al.  One-Stage Factor VIII Assays. , 2017, Methods in molecular biology.

[11]  F. Leebeek,et al.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients , 2016, Haematologica.

[12]  E. Nielsen,et al.  Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization , 2016, Journal of thrombosis and haemostasis : JTH.

[13]  S. Polinder,et al.  The “OPTI-CLOT” trial , 2015, Thrombosis and Haemostasis.

[14]  A. Iorio,et al.  Individualizing Factor Replacement Therapy in Severe Hemophilia , 2015, Seminars in Thrombosis & Hemostasis.

[15]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  Catherine M.T. Sherwin,et al.  Fundamentals of Population Pharmacokinetic Modelling , 2012, Clinical Pharmacokinetics.

[17]  T. Buclin,et al.  Safe and Effective Variability—A Criterion for Dose Individualization , 2012, Therapeutic drug monitoring.

[18]  Basic and translational science , 2011 .

[19]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  S. Björkman.  Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  R. Camire.  Hemophilia: basic and translational science , 2010, Expert review of hematology.

[22]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[23]  S. Jönsson,et al.  Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.

[24]  M. Makris,et al.  Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  Gabor Grothendieck,et al.  Lattice: Multivariate Data Visualization with R , 2008 .

[26]  K. Kurnik,et al.  Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  Mats O. Karlsson,et al.  Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.

[29]  A. Dorner,et al.  The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. , 1991, The Journal of biological chemistry.

[30]  D. Noe,et al.  Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. , 1986, Blood.